Bayer announced the start of a Phase III clinical development program “OCEANIC” to investigate the efficacy and safety of asundexian (BAY 2433334), an investigational...
Bristol Myers Squibb in collaboration with Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), announced results from the...
New results from a pre-specified, patient level, pooled analysis from the Phase III DAPA-HF and DELIVER trials demonstrated mortality benefit of FARXIGA® (dapagliflozin), compared...
Resecurity, a U.S. cybersecurity and intelligence company, announced its partnership with ECOMIL SAS to expand Resecurity's AI-driven cybersecurity solutions and threat intelligence services to...
